BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31648323)

  • 21. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
    Cook J; Johnson I; Higgins A; Sidana S; Warsame R; Gonsalves W; Gertz MA; Buadi F; Lacy M; Kapoor P; Dispenzieri A; Kourelis T; Dingli D; Fonder A; Hayman S; Hobbs M; Hwa YL; Kyle R; Leung N; Go R; Rajkumar VS; Kumar S
    Am J Hematol; 2021 Mar; 96(3):330-337. PubMed ID: 33326116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
    Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
    Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
    Palladini G; Russo P; Milani P; Foli A; Lavatelli F; Nuvolone M; Perlini S; Merlini G
    Haematologica; 2013 Mar; 98(3):433-6. PubMed ID: 22983583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
    Cohen OC; Sharpley F; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Fontana M; Whelan CJ; Martinez-Naharro A; Kyriakou C; Rabin N; Popat R; Yong K; Cheesman S; Shah R; Hawkins PN; Wechalekar AD
    Br J Haematol; 2020 May; 189(4):643-649. PubMed ID: 31984481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
    Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P
    Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
    Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J
    Blood; 2019 Oct; 134(16):1337-1345. PubMed ID: 31484647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
    Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
    Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
    Palladini G; Milani P; Foli A; Basset M; Russo F; Perlini S; Merlini G
    Blood; 2018 Feb; 131(5):525-532. PubMed ID: 29101236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
    Denman J; Manavi K; Cook M
    Int J STD AIDS; 2017 Sep; 28(10):1045-1047. PubMed ID: 28632471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
    Sanchorawala V; Patel JM; Sloan JM; Shelton AC; Zeldis JB; Seldin DC
    Haematologica; 2013 May; 98(5):789-92. PubMed ID: 23144200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
    Major A; Jakubowiak A; Derman B
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1000-e1008. PubMed ID: 35922273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
    Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
    Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
    Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
    Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.